WuXi Biologics (Cayman) Inc
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$96.30 | Rnxxvh | Wfjlhbm |
Wuxi Biologics Is a Global Biologics Contract Research, Development, and Manufacturing Organization
Business Strategy and Outlook
WuXi Biologics differentiates itself from other global well-established contract development and manufacturing organizations, with its “follow-and-win the molecule” and the “global dual-sourcing” strategies. Simply put, it provides end-to-end services for biological drugs from drug discovery all the way to clinical and commercial manufacturing. As such, WuXi has one of the largest bioreactor capacities for biological drug products. DPs are the noncommercialized therapeutic products used in the clinical trial phase. As a result, WuXi has been growing at a CAGR of 61.4% for the past eight years, much faster than that of global pharmaceutical sales or global CDMOs.